14440-47-2

Usage

Uses

Used in Pharmaceutical Industry:
(4-chloro-2-formylphenoxy)acetic acid is used as an intermediate in the synthesis of various pharmaceuticals for its unique reactivity and properties. It contributes to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, (4-chloro-2-formylphenoxy)acetic acid is utilized as a key component in the production of agrochemicals. Its chemical structure allows for the creation of effective compounds for agricultural use.
Used in Dye Production:
(4-chloro-2-formylphenoxy)acetic acid is used as a building block in the production of dyes. Its unique properties enable the development of dyes with specific characteristics for various applications.
Used in Organic Compounds Synthesis:
(4-chloro-2-formylphenoxy)acetic acid is also used in the synthesis of other organic compounds, where its chloro and formyl groups provide specific reactivity needed for the formation of complex organic molecules.

InChI:InChI=1/C9H7ClO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-4H,5H2,(H,12,13)

Upstream product

• 24581-96-2 methyl (4-chloro-2-formylphenoxy)acetate 
• 79-11-8 chloroacetic acid 
• 635-93-8 5-chlorosalicyclaldehyde 
• 17798-46-8 (4-chloro-2-formyl-phenoxy)-acetic acid ethyl ester 

Downstream Products

• 6386-63-6 2-hydroxymethyl-4-chlorophenyloxyacetic acid 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of thiazolidine-2,4-dione conjugates as PPAR-γ agonists

A library of synthesized conjugates of phenoxy acetic acid and thiazolidinedione 5a-m showed potent peroxisome proliferator activated receptor-γ (PPAR-γ) transactivation as well as significant blood glucose lowering effect comparable to the standard drugs pioglitazone and rosiglitazone. Most of the compounds showed higher docking scores than the standard drug rosiglitazone in the molecular docking study. Compounds 5l and 5m exhibited PPAR-γ transactivation of 54.21 and 55.41%, respectively, in comparison to the standard drugs pioglitazone and rosiglitazone, which showed 65.94 and 82.21% activation, respectively. Compounds 5l and 5m significantly lowered the blood glucose level of STZ-induced diabetic rats. Compounds 5l and 5m lowered the AST, ALT, and ALP levels more than the standard drug pioglitazone. PPAR-γ gene expression was significantly increased by compound 5m (2.00-fold) in comparison to the standard drugs pioglitazone (1.5-fold) and rosiglitazone (1.0-fold). Compounds 5l and 5m did not cause any damage to the liver and could be considered as promising candidates for the development of new antidiabetic agents.

Synthesis and aldose reductase inhibitory activity of a new series of 5- [[2-(ω-carboxyalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives

A new series of 5-[[2-(ω-carboxyalkoxy)aryl]methylene]-4-oxo-2- thioxothiazolidine derivatives was synthesized and evaluated for their potency as aldose reductase inhibitors (ARIs). Their activities were examined in terms of their inhibitory effect on rat lens aldose reductase in vitro and in terms of the preventive effect on sorbitol accumulation in the sciatic nerve of streptozotocin (STZ)-induced diabetic rats in vivo. Of these compounds, some of the naphthylmethylene thiazolidine derivatives were comparable to Zenarestat in the inhibitory potency in vitro and in vivo. In particular, compound 30 was 1.5 times more potent than Zenarestat in the in vivo activity, and had an adequate potency for clinical development.